CN1165652A - Meadow saffron alkaline pasting agent - Google Patents
Meadow saffron alkaline pasting agent Download PDFInfo
- Publication number
- CN1165652A CN1165652A CN 97104330 CN97104330A CN1165652A CN 1165652 A CN1165652 A CN 1165652A CN 97104330 CN97104330 CN 97104330 CN 97104330 A CN97104330 A CN 97104330A CN 1165652 A CN1165652 A CN 1165652A
- Authority
- CN
- China
- Prior art keywords
- colchicine
- alkaline
- pasting agent
- sensitive adhesive
- meadow saffron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A colchicine picking for treating acute gout is prepared from colchicine as active gout medicine, laurocapram as penetrating promoter and polyacrylic acid as pressure-sensitive adhesive through mixing and coating to mixture on film, and features high biological utilization rate, low ering toxic by-effect and convenient application.
Description
The present invention relates to be shaped as the pharmaceutical product that feature contains organic active ingredient particularly a kind of meadow saffron alkaline pasting agent with specific physical.
Colchicine treatment gout has had more than 200 year history, because of its to the selective antiinflammation of gouty arthritis, and generally acknowledged it is a kind of efficient antigout drug by medical circle both at home and abroad.The seventies, this medicine was successfully used to treat some cancer and Mediterranean fruit fly again.Colchicine can improve the liver function of liver cirrhosis patient in recent years, prolongs the time-to-live, and the treatment erythema elevatum diutinum, advanced schistosomiasis and lumbar intervertebral disc syndrome etc.American Pharmacopeia, British Pharmacopoeia, Pharmacopeia of Japan, Chinese Pharmacopoeia all connect version and record colchicine raw material and preparation thereof.Its dosage form is generally tablet and injection, and the intravenous injection local irritation is big; Gastrointestinal reactions such as nausea and vomiting, diarrhoea stomachache often appear in oral tablet, even poisoning manifestations such as popularity vascular lesion, kidney damage occur.Therefore clinician and patient require its dosage form and usage are improved." Sichuan medical science " 1983; (4) 6; P321 report selects for use dimethyl sulfoxide to make transdermal enhancer and colchicine compound external-use control cicatrix propagation, damages because dimethyl sulfoxide produces unhappy abnormal smells from the patient and produces general toxicity, is restricted in the use of some countries.
It is meadow saffron alkaline pasting agent that purpose of the present invention aims to provide the new pharmaceutical dosage form of a kind of percutaneous dosing treatment goat.
The present invention realizes by the weight portion proportioning of following prescription.
Colchicine 0.5-1.5 Laurel nitrogen ketone 2.5-3.0
Polyacrylic acid pressure sensitive adhesive 950.0-1050.0
Prescription optimum weight part proportioning of the present invention is:
Colchicine 1.5 Laurel nitrogen ketone 3.0
Polyacrylic acid pressure sensitive adhesive 1000.0
Main clinical application of the present invention: treatment acute gouty arthritis.
The preparation method of meadow saffron alkaline pasting agent:
Colchicine and Laurel nitrogen ketone with 1: 20 ratio stir, miscible, the gained suspension adds the polyacrylic acid pressure sensitive adhesive with 1: 1 ratio becomes medicine glue mixed liquor, the quick glue of pressurization is continued in the back that stirs, and stirs, and coats the film material and gets final product.
The meadow saffron alkaline pasting agent of making like this can be avoided the first pass effect of injection site and GI irritation and liver owing to having changed traditional treatment goat intravenous injection or oral administering mode, reduce the toxic and side effects of medicine, can improve bioavailability of medicament again, medication, drug withdrawal make things convenient for, and have no adverse reaction through experimental observation skin.
Below in conjunction with embodiment and process chart the present invention is encyclopaedized.
Accompanying drawing is the meadow saffron alkaline pasting agent process chart.
Taking by weighing colchicine 1.5Kg, Laurel nitrogen ketone 30Kg respectively fully stirs and makes it miscible for suspension, other gets polyacrylic acid pressure sensitive adhesive 31.5Kg is that 1: 1 ratio stirring and evenly mixing is a medicine glue mixed liquor 1, continuation adding pressure sensitive adhesive 968.5Kg stirs evenly and becomes medicine glue mixed liquor 2, adopt patent equipment spiral fashion so medicine film coating machine to coat on the film material with 5 meters speed of per minute, 35 ℃ of dryings, uviol lamps are sterilized, be added with silicon paper, be wound into compound film material, cut out and package spare.
Transdermal absorption test and the test of human body Transdermal absorption in the animal transdermal test in vitro absorption test of meadow saffron alkaline pasting agent, animal body, the result is: mice skin transdermal test in vitro absorption test cumulant is 61.8% of an application dose between 24 hours; It is 26.7% of application dose that the rat vivo transdermal absorbs cumulant; Human body Transdermal absorption cumulant is 25.4% of an application dose.
The animal pharmacodynamics test:
1. result of the test shows: the rat paw edema acute stage that MSU is brought out (causing scorching back 4 hours) each dosage group of meadow saffron alkaline pasting agent all can obviously suppress, particularly in the dosage group all can significantly suppress pedal swelling in 2-6 hours causing scorching back.
2. leukocytic the oozing out in each dosage group of meadow saffron alkaline pasting agent and the positive drug rabbit acute arthritis synovial membrane liquid that all can obviously suppress for oral group to be brought out by MSU relatively has the highly significant meaning with matched group.
3. to synovial tissue's pathological observation: the middle and high dosage group of meadow saffron alkaline pasting agent all has cell infiltration, synovial cell's degeneration and alleviates and inhibitory action.
The people shows consideration for the test result statistics
| Curative effect | The example number | Percentage ratio (%) |
| Respond well | ????40 | ????90.91 |
| Invalid | ????4 | ????9.09 |
Claims (2)
1. a meadow saffron alkaline pasting agent is made up of colchicine and transdermal enhancer, it is characterized in that this patch is to make by the weight portion proportioning of following prescription:
Colchicine 0.5-1.5 Laurel nitrogen ketone 2.5-3.0
Polyacrylic acid pressure sensitive adhesive 950.0-1050.0
2. patch according to claim 1 is characterized in that optimum weight part proportioning of this patch prescription is:
Colchicine 1.5 Laurel nitrogen ketone 3.0
Polyacrylic acid pressure sensitive adhesive 1000.0
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97104330 CN1165652A (en) | 1997-05-22 | 1997-05-22 | Meadow saffron alkaline pasting agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97104330 CN1165652A (en) | 1997-05-22 | 1997-05-22 | Meadow saffron alkaline pasting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1165652A true CN1165652A (en) | 1997-11-26 |
Family
ID=5167269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97104330 Pending CN1165652A (en) | 1997-05-22 | 1997-05-22 | Meadow saffron alkaline pasting agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1165652A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101062022B (en) * | 2007-05-31 | 2010-11-24 | 天津市中宝制药有限公司 | Colchicine patch absorbing from skin for treating acute goute arthritis and the preparing method thereof |
| CN102366403A (en) * | 2011-10-10 | 2012-03-07 | 薛巍 | Colchicine microemulsion transdermal agent, preparation method thereof and application thereof |
| CN105288192A (en) * | 2015-11-25 | 2016-02-03 | 范葵 | Appendiculate cremastra pseudobulb patch, preparation method and applications thereof |
| WO2024067722A1 (en) * | 2022-09-30 | 2024-04-04 | 北京德默高科医药技术有限公司 | Patch comprising colchicine and preparation method therefor and use thereof |
-
1997
- 1997-05-22 CN CN 97104330 patent/CN1165652A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101062022B (en) * | 2007-05-31 | 2010-11-24 | 天津市中宝制药有限公司 | Colchicine patch absorbing from skin for treating acute goute arthritis and the preparing method thereof |
| CN102366403A (en) * | 2011-10-10 | 2012-03-07 | 薛巍 | Colchicine microemulsion transdermal agent, preparation method thereof and application thereof |
| CN105288192A (en) * | 2015-11-25 | 2016-02-03 | 范葵 | Appendiculate cremastra pseudobulb patch, preparation method and applications thereof |
| WO2024067722A1 (en) * | 2022-09-30 | 2024-04-04 | 北京德默高科医药技术有限公司 | Patch comprising colchicine and preparation method therefor and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9066885B2 (en) | Advanced functional biocompatible polymeric matrix containing nano-compartments | |
| CN100569273C (en) | A kind of external Chinese medicine that is used for the treatment of skin tumour, tinea, wart, herpes | |
| CN101904812A (en) | The compositions and the method that are used for transdermal oxybutynin therapy | |
| DE112013001457T5 (en) | Transdermal application system | |
| US11833161B2 (en) | Compositions and methods for treatment of skin infections | |
| PL188153B1 (en) | Drug and manner of exterting a pharmacological effect on human organism by such drug | |
| CN1939316B (en) | Microsphere containing adriamycin, its usage and preparation | |
| CN102657602B (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
| CN102688483A (en) | Composition for treating dermatosis, preparation containing composition and preparation method thereof | |
| CN1165652A (en) | Meadow saffron alkaline pasting agent | |
| Ameena et al. | Cytocompatibility and wound healing activity of chitosan thiocolchicoside lauric acid nanogel in human gingival fibroblast cells | |
| CN1092961C (en) | Pharmaceutical with anti-high-blood-sugar function | |
| CN108272778A (en) | A kind of ursolic acid/insulin nano sustained release percutaneous drug administration preparation and preparation method thereof | |
| CN101036660A (en) | Estrogen gelatin medicine and the method for preparing the same | |
| WO2007013100A1 (en) | Gel formulation comprising platelet derived growth factor | |
| CN102008536B (en) | Tripterygium wilfordii hook extract cataplasm and preparation method thereof | |
| EP2015756A2 (en) | Methods for treating or preventing disorders using ecdysteroid compositions | |
| CN110522723A (en) | A kind of Metformin hydrochloride percutaneous drug administration preparation and preparation method thereof | |
| EP1397124B1 (en) | Use of antidiabetics for making a medicine with cicatrizing effect | |
| CN102391499B (en) | Preparation method of polymer for quickly releasing active components of masticinic acid under exciting of reduction | |
| RU2140259C1 (en) | Antibacterial pharmaceutical composition | |
| JPH0320218A (en) | Corn therapeutic agent | |
| CN1055634C (en) | Emplastrum for lowering blood viscosity | |
| BAMGBADE et al. | Antidiabetic Potential of The Leaf Extracts of Phragmanthera incana (Schum.) Balle Harvested on Albizia lebbeck | |
| CN1255115C (en) | Pharmaceutical product containing rare earth for treating acne and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |